Taselisib

CR-CSphCs were exposed to vemurafenib (1 µM, S1267 Selleckchem, Houston, TX, USA), cetuximab (20 µg/mL) and trastuzumab (10 µg/mL) (provided by Policlinico “Paolo Giaccone”, Palermo, Italy), as well as BKM120 (1 µM, S2247 Selleckchem, Houston, TX, USA), dinaciclib (10 nM, S2768 Selleckchem, Houston, TX, USA) and taselisib (1 µM, GDC-0032 Selleckchem, Houston, TX, USA). All the compounds, with the exception of dinaciclib, were refilled every 48 h. To evaluate the significance of the dinaciclib and taselisib combinatorial treatment, CR-CSphCs were exposed to different concentrations of dinaciclib (5, 10 and 25 nM) and taselisib (0.2, 0.5 and 1 µM) for 72 h and the data were analyzed with Synergy Finder software (version 2.0) [33 (link)] (Table 2). To obtain CAF-conditioned medium (CAF CM), CAFs were grown to subconfluence and maintained in SCM for 48 h. Before addition to the CR-CSphCs, the CAF CM was filtered with a 0.22 µm filter to remove any cell debris.